At1g13630 Antibody

What is At1g13630 and what protein does it encode?

At1g13630 is a gene locus in Arabidopsis thaliana that encodes ACBP3, one of six acyl-CoA-binding proteins found in this model plant species. ACBPs are characterized by their ability to bind acyl-CoA esters with varying affinities, playing critical roles in lipid metabolism and transport. The ACBP family in Arabidopsis includes proteins ranging from 10 kDa (ACBP6) to larger isoforms such as ACBP4 (73.1 kDa) and ACBP5 (71 kDa), each containing conserved acyl-CoA-binding domains and additional structural domains that suggest interactions with other proteins .

How specific are At1g13630 antibodies, and what cross-reactivity issues should researchers be aware of?

Commercial antibodies for plant proteins, including those targeting At1g13630, often suffer from specificity issues. Researchers should be cautious as many antibodies exhibit cross-reactivity with related protein family members, potentially leading to misidentification. For instance, the study of AT1R antibodies revealed significant specificity problems, with commercial antibodies often recognizing unrelated proteins . When developing antibodies for Arabidopsis ACBPs, researchers successfully generated specific antibodies using synthetic peptides unique to ACBP4 (amino acids 566-580) and ACBP5 (amino acids 554-566) for rabbit immunization, demonstrating a viable approach to minimize cross-reactivity .

What are the recommended protocols for western blot analysis using At1g13630 antibodies?

For effective western blot analysis of At1g13630-encoded proteins, extract proteins from Arabidopsis tissues using ice-cold extraction buffer (0.1 M TES, pH 7.8, 0.2 M NaCl, 1 mM EDTA, 2% β-mercaptoethanol, and 1 mM PMSF). Separate total proteins using SDS-PAGE and transfer to appropriate membranes such as Hybond-C. Block membranes in TTBS containing 5% nonfat milk for 2 hours, then incubate with primary antibodies for an additional 2 hours. After washing three times with TTBS, incubate with secondary antibody for 1 hour. For detection, either Amplified Alkaline Phosphatase Goat Anti-rabbit Immuno-blot Assay Kit or ECL Western Blotting Detection Kit can be used following manufacturer's instructions .

What controls should be included when validating a new At1g13630 antibody?

When validating a new At1g13630 antibody, researchers should include:

• Positive controls using recombinant proteins or overexpression lines

• Negative controls using knockout mutants (e.g., acbp4 mutant for ACBP4 antibodies)

• Peptide competition assays to confirm specificity

• Cross-reactivity testing against related family members

• Subcellular fractionation controls to verify localization patterns

These controls are essential to confirm antibody specificity and avoid misidentification, as demonstrated in the comprehensive validation approach used for ACBP4 and ACBP5 antibodies .

How can At1g13630 antibodies be used to investigate protein-protein interactions?

At1g13630 antibodies can be employed in co-immunoprecipitation (Co-IP) experiments to identify protein interactors. The structural domains of ACBPs, particularly the kelch motifs in ACBP4 and ACBP5, suggest interaction with protein partners as highlighted in research: "These two larger isoforms of ACBPs may function either alone or with possible protein partners interacting at their kelch motifs. Screening for their protein interactors by yeast two-hybrid system has already been initiated" . Researchers can use At1g13630 antibodies to pull down protein complexes followed by mass spectrometry analysis to identify novel interactors, providing insights into the broader functional networks of these proteins in plant cells.

What approaches are recommended for resolving subcellular localization discrepancies using At1g13630 antibodies?

To resolve subcellular localization discrepancies, implement a multi-method approach combining:

• Biochemical fractionation followed by western blot analysis using specific antibodies

• Immuno-electron microscopy on plant tissue sections

• Confocal microscopy of fluorescence-tagged proteins

This comprehensive approach successfully determined ACBP4 and ACBP5 localization to the cytosol: "Results from western blot analysis revealed that anti-ACBP4 antibodies cross-reacted with a band of apparent molecular mass of 73.1 kD, as predicted for ACBP4, in total protein and in the cytosol fraction" . When immunolocalization results conflict, consider testing multiple fixation and embedding protocols, as these parameters can significantly affect epitope accessibility.

How do researchers interpret potentially contradictory antibody-based findings across different experimental systems?

When faced with contradictory antibody-based findings, researchers should:

• Evaluate antibody specificity across different experimental conditions

• Consider the genetic background of plant materials used

• Assess potential post-translational modifications affecting epitope recognition

• Examine developmental or stress-induced changes in protein localization or expression

• Validate findings using complementary techniques such as mass spectrometry

For example, the localization studies of ACBP4 and ACBP5 required confirmation through multiple approaches: "To confirm the subcellular localization of ACBP4 and ACBP5 in the Arabidopsis cytosol, immuno-electron microscopy was carried out using transverse sections of leaves and roots of 2-week-old Arabidopsis" .

What are the optimal parameters for generating antibodies against At1g13630-encoded proteins?

When generating antibodies against At1g13630-encoded proteins, researchers should:

• Select unique peptide sequences to minimize cross-reactivity (critical for ACBPs with high sequence similarity)

• Target accessible regions of the protein (avoid transmembrane domains)

• Consider multiple immunization strategies and animal hosts

• Include affinity purification steps to enhance specificity

For example, researchers successfully generated specific antibodies for ACBP4 and ACBP5 by using synthetic peptides corresponding to unique regions: "To generate ACBP4- and ACBP5-specific antibodies, synthetic peptides (RMQTLQLRQELGEAE corresponding to amino acids 566 to 580 of ACBP4, and KEELAEIDTRNTE corresponding to amino acids 554 to 566 of ACBP5) were used for rabbit immunization" .

How can phenotypic analysis of knockout mutants complement antibody-based findings?

Phenotypic analysis of knockout mutants provides critical validation for antibody-based findings by:

• Confirming the specificity of observed protein signals

• Establishing functional relevance of protein localization patterns

• Revealing redundancy among protein family members

Research on the acbp4 knockout mutant demonstrated this approach: "Lipid profile analysis further revealed that an acbp4 knockout mutant showed decreases in membrane lipids (digalactosyldiacylglycerol, monogalactosyldiacylglycerol, phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol) while acbp4-complemented lines attained levels similar to wild type, suggesting that ACBP4 plays a role in the biosynthesis of membrane lipids" . The absence of severe phenotypic changes in the acbp4 mutant under normal conditions suggested functional redundancy with ACBP5, highlighting the importance of examining multiple family members.

What strategies can resolve false negative results when using At1g13630 antibodies?

To address false negative results:

• Modify protein extraction protocols to improve target protein solubility

• Optimize antibody concentration and incubation conditions

• Test alternative membrane types and blocking agents

• Enhance detection sensitivity using amplification systems

• Consider native versus denaturing conditions that may affect epitope accessibility

For example, the detection protocol for ACBP4 and ACBP5 employed both alkaline phosphatase and ECL detection systems to ensure optimal sensitivity: "Either the Amplified Alkaline Phosphatase Goat Anti-rabbit Immuno-blot Assay Kit (BioRad) or the ECL Western Blotting Detection Kit (Amersham) was used following the manufacturer's instructions to detect cross-reacting bands" .

How can researchers differentiate between specific and non-specific signals when using At1g13630 antibodies?

To differentiate between specific and non-specific signals:

• Include knockout mutants as negative controls

• Perform peptide competition assays

• Test pre-immune sera in parallel experiments

• Compare results across multiple detection methods

• Validate with recombinant protein standards

The challenge of antibody specificity is emphasized in research: "Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor (AT1R) protein" . This underscores the importance of rigorous validation approaches when working with any antibody, including those targeting At1g13630-encoded proteins.

How do At1g13630 antibodies compare with antibodies against other ACBP family members in terms of specificity and applications?

When comparing antibodies against different ACBP family members:

This comparative approach is supported by research demonstrating the strategic selection of unique peptide sequences for antibody generation to minimize cross-reactivity between structurally similar proteins .

What considerations should researchers keep in mind when comparing At1g13630 expression across different developmental stages or stress conditions?

When comparing At1g13630 expression across different conditions:

• Maintain consistent sampling protocols across all conditions

• Account for protein stability changes under different conditions

• Consider post-translational modifications that may affect antibody recognition

• Include loading controls appropriate for each condition

• Validate key findings with complementary techniques (qRT-PCR, proteomics)

The research on ACBPs demonstrates condition-specific effects: "Unlike the dgd1 mutant, or the mod1 and mgd1 mutants which are impaired in fatty acid biosynthesis, the acbp4 mutant did not exhibit phenotypic changes when grown under normal conditions" . This suggests that functional redundancy or condition-specific roles may complicate expression analysis, necessitating careful experimental design.

How might At1g13630 antibodies be applied in studying protein-lipid interactions?

At1g13630 antibodies could be invaluable for investigating protein-lipid interactions through:

• Immunoprecipitation followed by lipidomic analysis of bound lipids

• Immunolocalization studies during lipid stress conditions

• Co-localization with lipid biosynthesis enzymes or transporters

• Protein crosslinking studies to capture transient protein-lipid interactions

This approach is supported by findings that ACBPs play crucial roles in lipid metabolism: "Our current findings reinforce our hypothesis that ACBP4 and ACBP5 are likely involved in lipid trafficking in the cytosol" . Further investigation using specific antibodies could reveal the mechanisms by which these proteins facilitate lipid transport and metabolism in plant cells.

What emerging technologies might enhance the utility of At1g13630 antibodies in plant research?

Emerging technologies with potential to enhance At1g13630 antibody applications include:

• Proximity labeling methods (BioID, APEX) to identify spatial protein networks

• Super-resolution microscopy for precise subcellular localization

• Single-cell proteomics to examine cell-type specific expression

• Microfluidic antibody validation platforms for higher-throughput specificity testing

• CRISPR-engineered epitope tags to enhance antibody specificity and sensitivity

These approaches could address current limitations noted in research: "Screening for their protein interactors by yeast two-hybrid system has already been initiated and the identification of such interactors would be expected to further enhance our knowledge on ACBP4 and ACBP5" . Integration of antibody-based detection with these emerging technologies could significantly advance understanding of At1g13630-encoded protein functions.